Revenues from drugs subject to price reduction under Inflation Reduction Act not essential for R&D

Revenues from drugs subject to price reduction under Inflation Reduction Act not essential for R&D

New research from the Center for Integration of Science and Industry at Bentley University shows that public companies with products subject to price negotiations in the first two years of the Inflation Reduction Act (IRA) were more profitable than comparable companies in the S&P 500 and that revenues from these drugs were not essential for corporate operations or R&D. This research also shows the estimated margins from sales of these drugs exce…